At first, Krista Easom figured the little red bump on her foot was nothing more than a blister.
It didn’t hurt, but after a couple months, it didn’t go away either.
She booked an appointment with a dermatologist to have it removed. She wasn’t worried. Easom, a 24-year-old law school student from New Jersey, was healthy, had no family history of cancer and was getting ready to enjoy some time in her newly adopted city of Chicago.
That’s when she received the results from her dermatologist, who removed a part of the blister and had it tested.
It turns out that little red bump was malignant melanoma, the leading cause of skin cancer death in the United States. It’s a cancer that kills one person every hour, which translates to more than 8,700 Americans each year.
Further tests revealed that Easom’s melanoma had spread to her lymph nodes, which meant she needed a lymphadenectomy to have them removed. This major surgery includes a five-day stay in the hospital followed by an extensive recovery. About half of the patients who undergo this procedure suffer from wound infections because of the 12-inch incision’s hip-to-thigh location.
Easom and her family looked into her options and she was referred to Northwestern Medicine® surgical oncologists Jeffery D. Wayne, MD and Karl Bilimoria, MD, two of the very few surgeons in the country using a minimally invasive procedure to remove groin lymph nodes. This laparoscopic procedure may drastically reduce the recovery rate and chance of infection for patients like Easom.
“Only a handful of surgeons in the country are doing this and it makes a world of difference to the patient,” said Bilimoria, a surgical oncologist at Northwestern Memorial Hospital and an assistant professor of surgery at Northwestern University Feinberg School of Medicine. “Instead of a 12-inch scar, this laparoscopic procedure has only three very small incisions that total less than one inch. Because these incisions are so small, the chance of infection is far less. Instead of a five-day stay in the hospital, Krista went home the day after her surgery.”
Lymph nodes are the most frequent site of the spread of metastatic melanoma and surgically removing them is the only potential for a cure, Wayne said.
“Surgery is the only way to make sure we get all of the cancer,” Wayne said. “We want Krista to move on with her life. The minimally-invasive procedure was by far, the quickest and safest way for her to do that.”
Just a few weeks post-surgery, Easom is already on her way. She will have regular check-ups for awhile but her CT scans and blood tests show that the surgery successfully removed all of her cancer. Easom is participating in a national clinical trial to see if this minimally invasive procedure can help other melanoma patients.
The Latest on: Melanoma
- Skin Cancer: Melanoma, Basal Cell, Squamous Cell Carcinoma on February 19, 2019 at 12:35 pm
As much as we might enjoy spending time in the sun, the fact is it can be damaging to the skin. In fact, in some cases it can lead to skin cancer, the most common form of cancer diagnosed in the ... […]
- Keytruda Approved for the Adjuvant Treatment of Patients With Stage III Melanoma on February 19, 2019 at 12:24 pm
Merck announced that the Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following compl... […]
- Researchers develop new one-two punch against melanoma in mouse model on February 19, 2019 at 9:50 am
Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University School of Medicine report two new forms of an older anti-cancer agent they ... […]
- Melanoma Vaccine Market Will Grow at a Healthy CAGR by 2023 on February 19, 2019 at 8:37 am
The 'Global and Southeast Asia Melanoma Vaccine Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Melanoma Vaccine industry with a foc... […]
- Pembrolizumab Granted FDA Approval for Adjuvant Treatment of Stage 3 Melanoma on February 19, 2019 at 8:23 am
Officials with the FDA have granted approval to Merck’s pembrolizumab (Keytruda) for the adjuvant treatment of melanoma with involvement of lymph node(s) following complete resection, according to a p... […]
- Dr. Weber on FDA Approval of Pembrolizumab for Stage III Melanoma on February 19, 2019 at 6:24 am
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care in Melanoma, discusses the FDA approval of pembrol... […]
- FDA Approves Adjuvant Pembrolizumab in Stage III Melanoma on February 19, 2019 at 6:13 am
The FDA has approved the PD-1 inhibitor pembrolizumab (Keytruda) for the adjuvant treatment of patients with high-risk stage III melanoma with lymph node involvement following complete resection. 1 Th... […]
- FDA approves Keytruda for adjuvant treatment of melanoma on February 19, 2019 at 6:11 am
The FDA approved pembrolizumab for adjuvant treatment of patients who have melanoma with lymph node involvement who underwent complete resection. This is the first U.S. approval for pembrolizumab (Key... […]
- FDA Approves Keytruda for High-Risk, Advanced Melanoma on February 19, 2019 at 4:36 am
The Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) – an immunotherapy agent – for the treatment of patients with resected, high-risk, stage 3 melanoma, according to Merck, the ma... […]
- Smoking may limit the body's ability to fight melanoma on February 18, 2019 at 10:40 pm
NBC - Smoking may also limit the body's ability to fight the most deadly form of skin cancer. That's according to a new British study of over 700 patients with melanoma. It showed smokers were 40 perc... […]
via Google News and Bing News